AI news story
Google’s Isomorphic Labs to Raise Over $2 Billion in New Funding
Isomorphic Labs, an AI-powered drug discovery company spun out of Alphabet Inc.’s Google DeepMind, is in advanced discussions to raise more than $2 billion in a new round of funding, according to people familiar with the plan.
Editor's take
Isomorphic Labs, Alphabet's AI drug discovery venture, is nearing a significant funding round exceeding $2 billion. This substantial capital injection signals escalating investor confidence in AI's potential to accelerate pharmaceutical research and development. The move positions Isomorphic Labs to compete directly with established biotech firms and other AI-centric drug discovery startups like Recursion Pharmaceuticals and Insitro, which have also attracted considerable investment, though typically in smaller increments.
The scale of this funding suggests Isomorphic Labs plans aggressive expansion, potentially acquiring specialized talent and computational resources to expedite its pipeline development. Investors are betting on the success of DeepMind's foundational AI technologies, such as AlphaFold's protein structure prediction, being translated into tangible drug candidates. The critical question is whether Isomorphic can translate its advanced AI capabilities into a demonstrable track record of successful clinical trials, a notoriously long and expensive process, and ultimately, deliver novel therapeutics to market.
Signal score: 6
This event was corroborated by 8 independent sources. The signal score weighs cross-source corroboration, recency, source weight and topic salience. How we rank stories.
Original reporting
This story summarises reporting published by Bloomberg. Read the original article at Bloomberg.